Application of ΦSP-1 and ΦSP-3 as a therapeutic strategy against<i>Salmonella</i>Enteritidis infection using<i>Caenorhabditis elegans</i>as model organism

Augustine, Jeena; Gopalakrishnan, Mridula V.; Bhat, Sarita G.

doi:10.1111/1574-6968.12493

Cited by 13 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in bacteria‐eating nematodes (i.e. Caenorhabditis elegans ; Augustine et al ) or the larger wax moth ( Galleria mellonella ) larvae are becoming increasingly popular, due to their numerous advantages over higher animal models, including the lack of requirement for ethical approval, simple growth conditions and shorter life spans (Manohar et al ).…”

Section: Nonclinical Studiesmentioning

confidence: 99%

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Kwiatek

Parasion²,

Nakonieczna

2019

J Appl Microbiol

View full text Add to dashboard Cite

Summary Bacteriophages, highly prevalent in all environments, have found their use in medicine as an alternative or complement to antibiotics. The therapeutic use of bacteriophages was particularly popular in the 1920s and 1930s, until the discovery and introduction of antibiotics. Due to the dynamic growth of antibiotic resistance among bacterial strains, numerous international institutions (such as the FDA) have declared the search for novel treatment modalities to be of the highest priority. To date, bacteriophage therapy has not been registered for general use in Western countries. The regulation of biological medicinal products (within medicinal product regulation) does not contain a specific documentation frame for bacteriophages (only for vaccines, blood derived products, etc.) which, as active substances, need to meet specific requirements. Recently, the FDA allowed bacteriophage therapy to be used in the United States, via the Emergency Investigational New Drug scheme; clinical trials to compare the safety and efficacy of bacteriophage therapy are also permitted. To date, several therapeutic products of this type have made it to phase I or II; some clinical programmes have also been completed. This article cites numerous animal model studies and registered clinical trials, showing the safety and effectiveness of bacteriophage therapy, including infections caused by bacterial strains resistant to antibiotic treatment.

show abstract

Section: Nonclinical Studiesmentioning

confidence: 99%

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Kwiatek

Parasion²,

Nakonieczna

2019

J Appl Microbiol

View full text Add to dashboard Cite

show abstract

“…Phage concentration in the CSF was 10-fold higher than that in blood, demonstrating the capacity of phages to cross the blood-CSF barrier; work in humans by Ghose et al (2019) has also recently confirmed this finding. Other studies have shown effective treatment of keratitis in mice (Furusawa et al, 2016), otitis media in dogs (Hawkins et al, 2010), sinusitis in sheep (Drilling et al, 2014), and systemic infections in zebrafish (Al-Zubidi et al, 2019;Cafora et al, 2019) and moth larvae (Hall et al, 2012;Augustine et al, 2014;Nale et al, 2016a;Manohar et al, 2018;Jeon et al, 2019), supporting the idea that phage therapy can be studied in a broad range of infection models and animal species.…”

Section: Other Infectionsmentioning

confidence: 82%

Animal Models of Phage Therapy

2021

View full text Add to dashboard Cite

Amidst the rising tide of antibiotic resistance, phage therapy holds promise as an alternative to antibiotics. Most well-designed studies on phage therapy exist in animal models. In order to progress to human clinical trials, it is important to understand what these models have accomplished and determine how to improve upon them. Here we provide a review of the animal models of phage therapy in Western literature and outline what can be learned from them in order to bring phage therapy closer to becoming a feasible alternative to antibiotics in clinical practice.

show abstract

“…These results show that C. elegans can be a useful animal model for assessing the efficacy of phage therapy. 90 , 91 …”

Section: In Vivo Animal Trials Of Phage Therapymentioning

confidence: 99%

The applications of animal models in phage therapy: An update

Khan

Manohar

Gondil

et al. 2023

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The rapid increase in antibiotic resistance presents a dire situation necessitating the need for alternative therapeutic agents. Among the current alternative therapies, phage therapy (PT) is promising. This review extensively summarizes preclinical PT approaches in various in-vivo models. PT has been evaluated in several recent clinical trials. However, there are still several unanswered concerns due to a lack of appropriate regulation and pharmacokinetic data regarding the application of phages in human therapeutic procedures. In this review, we also presented the current state of PT and considered how animal models can be used to adapt these therapies for humans. The development of realistic solutions to circumvent these constraints is critical for advancing this technology.

show abstract

Application of ΦSP-1 and ΦSP-3 as a therapeutic strategy againstSalmonellaEnteritidis infection usingCaenorhabditis elegansas model organism

Cited by 13 publications

References 28 publications

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Therapeutic bacteriophages as a rescue treatment for drug‐resistant infections – anin vivostudies overview

Animal Models of Phage Therapy

The applications of animal models in phage therapy: An update

Contact Info

Product

Resources

About